Our mission is to cure autoimmune diseases,
not just temper their symptoms.
Founded in 2019, RheumaGen is a preclinical cell and gene therapy company developing cures for autoimmune diseases by attacking them at their source: the Human Leukocyte Antigen (HLA) gene.
Why target the HLA gene? Learn about our science here.
Our Values
We tackle big problems. We look for science-based, patient-friendly solutions.
Patient-Focus
We think of our future patients as if they were family.
Excellence
We strive for excellence in everything we do.
Integrity
We insist on integrity in our science and our business.
Our Team
-
Richard Freed
CEO & CO-FOUNDER
-
Brian Hart
COO & CO-FOUNDER
-
Brian Freed, PhD
CHIEF SCIENCE OFFICER & CO-FOUNDER
-
Ryan Hart
CHIEF LEGAL OFFICER
-
Tate Hermanson
VICE PRESIDENT, FINANCE
-
B Robert Mozayeni, MD
CHIEF MEDICAL OFFICER
Our research partners at ClinImmune Cell & Gene Therapy, the academic biotech within the University of Colorado where our HLA gene editing technology was invented, have unique expertise in the HLA gene. ClinImmune has a proven track record of success with 20+ years of organ and stem cell transplantation experience, 2 FDA licenses, and is actively supporting 20+ cell therapy clinical trials. To contact us and learn more about how we’re working together to change the fight against autoimmune diseases, click here .
ClinImmune Partnership: Experience & Expertise
-
Christina Roark, PhD
Associate Director, ClinImmune
-
Louise Helander, MD
Medical Director, ClinImmune
-
Amy McKee, PhD
Chief Development Officer, ClinImmune
-
Catherine Winters
Director of Regulatory Affairs, ClinImmune
Advisors
-
Prof. Dr. Georg Schett